ArticleJournal of global health2025
Characteristics of indications, clinical trial evidence, clinical benefits and the costs of price-negotiated multi-indication drugs for solid tumours in China.
Article in Journal of global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical value and cost-effectiveness analysis of conditionally approved anticancer drugs in China from 2015 to 2023.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer is a leading cause of death globally, with China accounting for a significant portion of new cases and deaths. The Government of China has introduced the National Drug Price Negotiation (NDPN) policy to mitigate the high costs of anticancer drugs, especially multi-indication drugs, aimed at improving patient access to effective treatments. Methods: In this retrospective study, we examined 24 multi-indication anticancer drugs for solid tumours included in the National Reimbursement Drug List (NRDL) between 2016 and 2023. We collected characteristics of indication, clinical trial evidence, and clinical benefits of these drugs, calculated monthly drug costs, and assessed the associations the two by regression and correlation analyses. Results: We observed a significant reduction in the median monthly drug cost from USD 3863.08 before NDPN to USD 732.91 after their inclusion in the NRDL. However, the correlation analyses showed no significant relationships between drug costs and characteristics of indications, clinical trial evidence, and clinical benefits, while American Society of Clinical Oncology Value Framework scores demonstrated a negative correlation with costs, indicating that pricing may not accurately reflect clinical benefits. Conclusions: While we found that the NDPN policy has significantly reduced drug costs, we did not observe a significant correlation between costs and specific characteristics. This highlights a need for a more transparent pricing mechanism linked to clinical efficacy to improve the accessibility and affordability of cancer therapies that effectively balance the interests of pharmaceutical companies, patients, and health insurance funds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.